GCM
CRSP icon

Gables Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Gables Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
2,000
-2,000
-50% -$105K 0.04% 189
2026
Q1 		$190K Buy
+4,000
New +$211K 0.08% 138

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gables Capital Management's CRSP Position: Q2 2026 in Review

Gables Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 50% in Q2 2026, selling an estimated $105K and leaving 2,000 shares worth $109K. The position accounts for 0.04% of the portfolio, ranked #189.

Gables Capital Management first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. The position peaked at $190K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Gables Capital Management held 2,000 shares of CRISPR Therapeutics worth $109K as of Q2 2026.
  • Gables Capital Management sold 2,000 CRISPR Therapeutics shares in Q2 2026, an estimated $105K.
  • CRISPR Therapeutics made up 0.04% of Gables Capital Management's portfolio in Q2 2026, its #189 holding.
  • Gables Capital Management first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Gables Capital Management's CRISPR Therapeutics position peaked at $190K in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.